Overview on Hepatitis B vaccination

Saber, Mona Ali; Sarhan, Hatem Abdul-Monsef; Fouad, Yasser; Elsayed, Mahmoud M. A.; Hassnine, Alshymaa A.

doi:10.21608/ejhm.2022.215573

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…60-70% of recombinant therapeutics produced since then have been in mammalian cells [7], including the first recombinant therapeutic drug tissue plasminogen approved in 1986. Approval of recombinant vaccines against hepatitis A & B also was resulted from the application of rDNA technology [8,9].…”

Section: Introductionmentioning

confidence: 99%

Perspective Chapter: Advanced Process Control and Automation with Special Focus on Emerging Continuous Bioprocessing

Chemmalil,

Chumsae,

et al. 2024

Technologies in Cell Culture - A Journey From Basics to Advanced Applications

View full text Add to dashboard Cite

Legacy batch processing carried out in pharmaceutical and biopharmaceutical sectors is undergoing transformation to adopt the next generation continuous processing to produce safe and effective drugs with better efficiency and consistency at a reduced cost. To facilitate innovative continuous processing, enabled by an end-to-end process with a single uninterrupted production scenario, it is essential to generate real-time or near-real-time data using process analytical technology (PAT), which has been defined by the FDA as a system for designing, analyzing, and controlling manufacturing through timely measurements to ensure final product quality. Based on quality by design (QbD) principles, PAT-enabled data monitoring is essential for the timely control of critical process parameters (CPPs) and critical quality attributes (CQAs) to keep the process in a desired state of control to achieve a predefined product quality. Based on QbD philosophy, quality cannot be tested into products; it should be built-in or should be by design. Deployment of PAT tools for real-time monitoring is integral to align with the guiding principles of QbD-enabled workflow to enhance process and product understanding to administer a control strategy to keep the process within the design space. Aim of this chapter is to highlight the recent advancements in PAT tool-development to monitor and control CPPs and CQAs.

show abstract

Section: Introductionmentioning

confidence: 99%

Perspective Chapter: Advanced Process Control and Automation with Special Focus on Emerging Continuous Bioprocessing

Chemmalil,

Chumsae,

et al. 2024

Technologies in Cell Culture - A Journey From Basics to Advanced Applications

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) is the third most common cancer after lung and breast cancer and the third most common cause of death due to cancer globally [ 4 , 5 ]. Each year, approximately 1 million new CRC cases are diagnosed in both men and women worldwide [ 6 , 7 ]. It is characterized by out-of-control growth in the colon or rectum or cecum.…”

Section: Introductionmentioning

confidence: 99%

Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer

et al. 2023

View full text Add to dashboard Cite

Gefitinib (GFT) is a tyrosine kinase inhibitor drug used as a first-line treatment for patients with advanced or metastatic non-small cell lung, colon, and breast cancer. GFT exhibits low solubility and hence low oral bioavailability, which restricts its clinical application. One of the most important trends in overcoming such problems is the use of a vesicular system. Cubosomes are considered one of the most important vesicular systems used to improve solubility and oral bioavailability. In this study, GFT cubosomal nanoparticles (GFT-CNPs) were prepared by the emulsification method. The selected formulation variables were analyzed and optimized by full factorial design and response surface methodology. Drug entrapment efficiency (EE%), transmission electron microscopy, particle size, polydispersity index, in vitro release and its kinetics, and the effect of storage studies were estimated. The chosen GFT-CNPs were subjected to further investigations as gene expression levels of tissue inhibitors of metalloproteinases-1 (TIMP-1) and matrix metalloproteinases-7 (MMP-7), colon biomarkers, and histopathological examination of colon tissues. The prepared GFT-CNPs were semi-cubic in shape, with high EE%, smaller vesicle size, and higher zeta potential values. The in vivo data showed a significant decrease in the serum level of embryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and gene expression level of TIMP-1 and MMP-7. Histopathological examination showed enhancement in cancer tissue and highly decreased focal infiltration in the lamina propria after treatment with GFT-CNPs.

show abstract

A Novel C@Fe@Cu Nanocomposite Loaded with Doxorubicin Tailored for the Treatment of Hepatocellular Carcinoma

et al. 2022

View full text Add to dashboard Cite

High mortality and morbidity rates are related to hepatocellular carcinoma (HCC), which is the most prevalent type of liver cancer. A new vision for cancer treatment and cancer cell targeting has emerged with the application of nanotechnology, which reduces the systemic toxicity and adverse effects of chemotherapy medications while increasing their effectiveness. It was the goal of the proposed work to create and investigate an anticancer C@Fe@Cu nanocomposite (NC) loaded with Doxorubicin (DOX) for the treatment of HCC. Scanning and transmission electron microscopes (SEM and TEM) were used to examine the morphology of the produced NC. The formulation variables (DOX content, C@Fe@Cu NC weight, and stirring speed) were analyzed and optimized using Box-Behnken Design (BBD) and Response Surface Methodology (RSM). Additionally, X-ray diffraction patterns (XRD) and Fourier Transform Infrared (FTIR) were investigated. Doxorubicin and DOX- loaded C@Fe@Cu NC (DOX-C@Fe@Cu NC) were also assessed against HEPG2 cells for anticancer efficacy (Hepatic cancer cell line). The results revealed the formation of C@Fe@Cu NC with a mean size of 7.8 nm. A D-R model with a mean size of 24.1 nm best fits the adsorption behavior of DOX onto the C@Fe@Cu NC surface. DOX-C@Fe@Cu NC has also been demonstrated to have a considerably lower IC50 and higher cytotoxicity than DOX alone in an in vitro investigation. Therefore, DOX-C@Fe@Cu NC is a promising DOX delivery vehicle for the full recovery of HCC.

show abstract

Overview on Hepatitis B vaccination

Cited by 3 publications

References 0 publications

Perspective Chapter: Advanced Process Control and Automation with Special Focus on Emerging Continuous Bioprocessing

Perspective Chapter: Advanced Process Control and Automation with Special Focus on Emerging Continuous Bioprocessing

Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer

A Novel C@Fe@Cu Nanocomposite Loaded with Doxorubicin Tailored for the Treatment of Hepatocellular Carcinoma

Contact Info

Product

Resources

About